Navigation Links
Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
Date:10/16/2007

">http://www.exelixis.com.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements related to the future development and potential efficacy, safety and tolerability of XL784 and the timing of the submission of XL784 data to GSK. Words such as "may," "will," "expects" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Exelixis' current expectations. Forward-looking statements involve risks and uncertainties. Exelixis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the results of any failure of XL784 to demonstrate safety and efficacy in clinical testing, risks related to Exelixis' arrangement with SEI and Exelixis' dependence on and relationship with GSK. These and other risk factors are discussed under "Risk Factors" and elsewhere in Exelixis' Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 and Exelixis' other filings with the Securities and Exchange Commission. Exelixis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Exelixis' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... CHENGDU, China , Jan. 23, 2015 Tianyin ... pharmaceutical company that specializes in the development and sale ... branded generics and active pharmaceutical ingredients (API) today announced ... Facility (JCM) API operation. 1. Following the ...
(Date:1/22/2015)... 22, 2015  ResMed Inc. (NYSE: RMD ) today ... for the quarter was $423.0 million, a 10 percent increase ... percent increase on a constant currency basis). Net income was ... quarter ended December 31, 2013. Diluted earnings per share for ...
(Date:1/22/2015)... , Jan. 22, 2015  Profil Institute for Clinical ... diabetes and obesity, announced today a new textbook,  Translational ... published by Springer, a leading global scientific publisher. ... and illustrate techniques for use in early phase clinical ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3
... Calif., Dec. 7, 2011 Rigel Pharmaceuticals, Inc. (Nasdaq: ... the company,s president and chief operating officer, is scheduled ... Annual Healthcare Conference in New York City on Wednesday, ... (Logo: http://photos.prnewswire.com/prnh/20030226/RIGLLOGO ) To ...
... 7, 2011   Talyst has released an updated ... The bar code technology ensures virtually 100% of medications ... The improved AutoLabel is a complete ... and white transfer labels to improve patient safety at ...
Cached Medicine Technology:Talyst Updates Its AutoLabel® Solution 2
(Date:1/22/2015)... West Hollywood, California (PRWEB) January 22, 2015 The ... 22, 2015 at 10 a.m., to commemorate the 42nd anniversary of ... the United States. , “It’s been 42 years since the Roe ... to choose is still as present as ever,” said City of ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put together ... by up to 30lbs in less than 12 weeks without ... Stevenson, prompting an investigative review. , “Our Incredible Bulk ... formula that allows the body to pack on a massive ...
(Date:1/22/2015)... 22, 2015 Juvent Sports ( http://www.juventsports.com ... 2015 PGA Merchandise Show to bestow a Juvent Sports ... amateur golfer, Arlene McKitrick. The award commemorated and congratulated ... tournament win. She won her first amateur tournament in ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting the basic ... , Purchasing an accidental death and dismemberment rider for a ... rider provides benefits if the insured dies in an accident. ... of life insurance. , AD&D is not expensive and ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative ... design to treat specific body parts and muscle groups. , ... easy to use patented cold therapy machine with the innovative ... and muscle injuries. IsoComforter has become the industry leader ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... $2 million pilot grant to fund the new ... Dartmouth. The grant is jointly funded by the ... National Institute for Environmental Health Sciences (NIEHS). Dartmouth,s ... are undertaking interdisciplinary research to assist public health ...
... ORLANDO A new drug appears to help chronic myeloid ... and second-line drugs have failed them or because their cancer ... start, researchers reported at the 52nd Annual Meeting of the ... trial, the drug ponatinib produced major or complete hematologic responses ...
... from four innovative studies help answer outstanding questions about ... Research will be presented today at the 52nd Annual ... there is no increase in overall cancer risk in ... of a double cord blood stem cell transplant is ...
... blood transfusions combined with daily medication to remove the ... the risk of recurrent strokes in young patients with ... a multicenter trial that includes St. Jude Children,s Research ... treatments for the potentially life-threatening problem of iron overload ...
... VanTine HealthDay Reporter , MONDAY, Dec. 6 ... school and in the court system than straight teens ... study suggests. "Our analysis found that, consistently, ... of being punished by school and criminal-justice authorities than ...
... Amanda Gardner HealthDay Reporter , SUNDAY, Dec. ... report that they managed to "correct" a malfunctioning gene ... disorder that leads to prolonged bleeding from even minor ... to certain cancers and dangerous infections. However, one ...
Cached Medicine News:Health News:Dartmouth receives $2 million grant for children's health research center 2Health News:Phase I trial indicates ponatinib may thwart most resistant CML 2Health News:Studies highlight role of stem cell transplant procedures for blood cancer treatment 2Health News:Studies highlight role of stem cell transplant procedures for blood cancer treatment 3Health News:Studies highlight role of stem cell transplant procedures for blood cancer treatment 4Health News:Studies highlight role of stem cell transplant procedures for blood cancer treatment 5Health News:Studies highlight role of stem cell transplant procedures for blood cancer treatment 6Health News:Studies highlight role of stem cell transplant procedures for blood cancer treatment 7Health News:Studies highlight role of stem cell transplant procedures for blood cancer treatment 8Health News:Studies highlight role of stem cell transplant procedures for blood cancer treatment 9Health News:Studies highlight role of stem cell transplant procedures for blood cancer treatment 10Health News:2 studies provide insight into stroke risk and prevention in young sickle cell anemia patients 2Health News:2 studies provide insight into stroke risk and prevention in young sickle cell anemia patients 3Health News:Gay Teens Punished More Harshly Than Straight Peers: Analysis 2Health News:Gay Teens Punished More Harshly Than Straight Peers: Analysis 3Health News:Gene Therapy Corrected Rare Bleeding Disorder: Study 2Health News:Gene Therapy Corrected Rare Bleeding Disorder: Study 3
... Pessary is used for a ... or procidentia. It has drainage ... comes in nine sizes. The ... folds over for insertion, and ...
... The ring pessary, available ... and without support, is a ... first to second degree prolapse. ... also be used on an ...
In the CCU, ED, or anywhere ECG records are needed, the Pyramis ECG Management System provides instant access to information, automating the process of managing information and eliminating time spent...
... female urinary stress incontinence (SUI) with a ... (BioArcTM SP) or a transobturator (BioArcTM TO) ... system combining synthetic and biologic materials. It ... The BioArc utilizes a polypropylene mesh for ...
Medicine Products: